Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity

Am J Ophthalmol. 2011 Feb;151(2):353-7.e1. doi: 10.1016/j.ajo.2010.08.037. Epub 2010 Dec 18.

Abstract

Purpose: To determine the vitreous levels of angiopoietin (Ang)-1 and Ang-2 in eyes with retinopathy of prematurity (ROP), and to determine the correlation between the 2 levels.

Design: Retrospective case-control study.

Methods: Forty-eight eyes with stage 4 ROP were studied. Six eyes with congenital cataract were used as controls. The ROP eyes were classified by the vascular activity into highly (n = 22), moderately (n = 15), and mildly (n = 11) vascular-active ROP. Eyes with highly vascular-active ROP initially received 0.5 mg of intravitreal bevacizumab (IVB) and underwent vitrectomy within 1 week. The others underwent vitrectomy without IVB. Vitreous samples were collected at the beginning of vitrectomy, and the vitreous levels of Angs were measured by enzyme-linked immunosorbent assay.

Results: The mean concentrations of Ang-1 and Ang-2 were 201.9 and 7832.1 pg/mL in highly vascular-active ROP eyes, 216.1 and 7731.2 pg/mL in moderately vascular-active ROP eyes, 533.8 and 1685.9 pg/mL in mildly vascular-active ROP eyes, and 0 and 41.5 pg/mL in control eyes. The vitreous Ang-1 level was significantly higher (P < .05) in highly, moderately, and mildly vascular-active ROP eyes than in control eyes. The vitreous Ang-2 level was significantly higher (P < .05) in highly and moderately vascular-active ROP eyes than in control eyes. There was a significant negative correlation (r = -0.406; P = .040) between the Ang-1 and Ang-2 levels in moderately and mildly vascular-active ROP eyes.

Conclusions: The balance of Ang-1 and Ang-2 in the vitreous may be important in the pathogenesis of ROP.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Angiopoietin-1 / metabolism*
  • Angiopoietin-2 / metabolism*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Case-Control Studies
  • Cataract / congenital
  • Cataract / metabolism
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Fluorescein Angiography
  • Gestational Age
  • Humans
  • Infant, Extremely Low Birth Weight
  • Infant, Newborn
  • Male
  • Retinopathy of Prematurity / diagnosis
  • Retinopathy of Prematurity / drug therapy
  • Retinopathy of Prematurity / metabolism*
  • Retrospective Studies
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors
  • Vitrectomy
  • Vitreous Body / metabolism*

Substances

  • Angiogenesis Inhibitors
  • Angiopoietin-1
  • Angiopoietin-2
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A
  • Bevacizumab